Published in BMC Cancer on December 03, 2010
3,3'-diindolylmethane induces activating transcription factor 3 (ATF3) via ATF4 in human colorectal cancer cells. J Nutr Biochem (2012) 0.97
The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins. J Biol Chem (2014) 0.94
High-amylose resistant starch increases hormones and improves structure and function of the gastrointestinal tract: a microarray study. J Nutrigenet Nutrigenomics (2012) 0.94
Loss of ATF3 promotes Akt activation and prostate cancer development in a Pten knockout mouse model. Oncogene (2014) 0.94
Systems analysis of ATF3 in stress response and cancer reveals opposing effects on pro-apoptotic genes in p53 pathway. PLoS One (2011) 0.90
P53 mutations in colorectal cancer - molecular pathogenesis and pharmacological reactivation. World J Gastroenterol (2015) 0.86
STAT5b as molecular target in pancreatic cancer--inhibition of tumor growth, angiogenesis, and metastases. Neoplasia (2012) 0.85
Expression of core 3 synthase in human pancreatic cancer cells suppresses tumor growth and metastasis. Int J Cancer (2013) 0.82
Expression and clinical significance of activating transcription factor 3 in human breast cancer. Iran J Basic Med Sci (2013) 0.81
Activating transcription factor 3-mediated chemo-intervention with cancer chemokines in a noncanonical pathway under endoplasmic reticulum stress. J Biol Chem (2014) 0.80
Upregulation of ATF-3 is correlated with prognosis and proliferation of laryngeal cancer by regulating Cyclin D1 expression. Int J Clin Exp Pathol (2013) 0.80
Detection of gene communities in multi-networks reveals cancer drivers. Sci Rep (2015) 0.79
Small molecule inhibition of cytoskeletal dynamics in melanoma tumors results in altered transcriptional expression patterns of key genes involved in tumor initiation and progression. Cancer Genomics Proteomics (2011) 0.79
The common stress responsive transcription factor ATF3 binds genomic sites enriched with p300 and H3K27ac for transcriptional regulation. BMC Genomics (2016) 0.77
Retracted ATF3 and extracellular matrix-related genes associated with the process of chronic obstructive pulmonary. Lung (2014) 0.77
The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells. Br J Pharmacol (2015) 0.77
Activating transcription factor 3 promotes malignance of lung cancer cells in vitro. Thorac Cancer (2017) 0.75
ASBEL-TCF3 complex is required for the tumorigenicity of colorectal cancer cells. Proc Natl Acad Sci U S A (2016) 0.75
In Vitro Anticancer Activity of Phlorofucofuroeckol A via Upregulation of Activating Transcription Factor 3 against Human Colorectal Cancer Cells. Mar Drugs (2016) 0.75
Ribosomal protein L34 promotes the proliferation, invasion and metastasis of pancreatic cancer cells. Oncotarget (2016) 0.75
Site-specific gene expression profiling as a novel strategy for unravelling keloid disease pathobiology. PLoS One (2017) 0.75
Enhanced Therapeutic Treatment of Colorectal Cancer Using Surface-Modified Nanoporous Acupuncture Needles. Sci Rep (2017) 0.75
Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell (2003) 3.25
Heat shock protein 90. Curr Opin Oncol (2003) 2.73
Chaperoning signaling pathways: molecular chaperones as stress-sensing 'heat shock' proteins. J Cell Sci (2002) 2.58
Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell (2008) 2.49
Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol (2008) 2.41
Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med (Berl) (2004) 2.32
Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther (2004) 2.16
Role for activating transcription factor 3 in stress-induced beta-cell apoptosis. Mol Cell Biol (2004) 2.10
Activating transcription factor 3, a stress-inducible gene, suppresses Ras-stimulated tumorigenesis. J Biol Chem (2006) 1.99
A potential dichotomous role of ATF3, an adaptive-response gene, in cancer development. Oncogene (2007) 1.95
Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. Cancer Res (2003) 1.61
The regulation of ATF3 gene expression by mitogen-activated protein kinases. Biochem J (2007) 1.52
Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. Am J Pathol (2003) 1.45
A biochemical rationale for the anticancer effects of Hsp90 inhibitors: slow, tight binding inhibition by geldanamycin and its analogues. Proc Natl Acad Sci U S A (2006) 1.38
The tumor metastasis suppressor gene Drg-1 down-regulates the expression of activating transcription factor 3 in prostate cancer. Cancer Res (2006) 1.35
The anti-invasive activity of cyclooxygenase inhibitors is regulated by the transcription factor ATF3 (activating transcription factor 3). Mol Cancer Ther (2005) 1.29
Death by chaperone: HSP90, HSP70 or both? Cell Cycle (2009) 1.22
Induction of activating transcription factor 3 by anoxia is independent of p53 and the hypoxic HIF signalling pathway. Oncogene (2006) 1.14
Involvement of transcriptional repressor ATF3 in acceleration of caspase protease activation during DNA damaging agent-induced apoptosis. J Cell Physiol (2001) 1.09
A splice variant of stress response gene ATF3 counteracts NF-kappaB-dependent anti-apoptosis through inhibiting recruitment of CREB-binding protein/p300 coactivator. J Biol Chem (2005) 1.08
Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor. Ann Surg (2005) 1.06
Epidermal hyperplasia and oral carcinoma in mice overexpressing the transcription factor ATF3 in basal epithelial cells. Mol Carcinog (2007) 0.99
Mutant p53 protects cells from 12-O-tetradecanoylphorbol-13-acetate-induced death by attenuating activating transcription factor 3 induction. Cancer Res (2006) 0.98
Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo. Mol Cancer Ther (2007) 0.92
Inhibitory effect of ATF3 antisense oligonucleotide on ectopic growth of HT29 human colon cancer cells. Jpn J Cancer Res (2000) 0.91
Angiopoietin-1 inhibits tumour growth and ascites formation in a murine model of peritoneal carcinomatosis. Br J Cancer (2002) 0.91
Role of activating transcription factor 3 on TAp73 stability and apoptosis in paclitaxel-treated cervical cancer cells. Mol Cancer Res (2008) 0.88
ATF3 gene regulates cell form and migration potential of HT29 colon cancer cells. Oncol Res (2001) 0.84
Microsatellite instability in tumor and nonneoplastic colorectal cells from hereditary non-polyposis colorectal cancer and sporadic high microsatellite-instable tumor patients. Pathobiology (2000) 0.78
Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg (2012) 19.78
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med (2002) 7.06
Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest (2004) 5.14
Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology (2009) 4.03
PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis. J Hepatol (2006) 3.50
A new pumpless extracorporeal interventional lung assist in critical hypoxemia/hypercapnia. Crit Care Med (2006) 3.24
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol (2013) 3.00
Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology (2004) 2.45
A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology (2003) 2.40
Dynamic imaging of cancer growth and invasion: a modified skin-fold chamber model. Histochem Cell Biol (2008) 2.39
Regulation of AID expression in the immune response. J Exp Med (2007) 2.35
Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat Genet (2005) 2.20
Living donor liver transplantation: the Asian perspective. Transplantation (2014) 2.13
Portal pressure <15 mm Hg is a key for successful adult living donor liver transplantation utilizing smaller grafts than before. Liver Transpl (2010) 2.02
Multicentric evaluation of model for end-stage liver disease-based allocation and survival after liver transplantation in Germany--limitations of the 'sickest first'-concept. Transpl Int (2010) 1.99
Perioperative changes in nutritional parameters and impact of graft size in patients undergoing adult living donor liver transplantation. Liver Transpl (2014) 1.97
Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis. PLoS One (2010) 1.94
Hepatocyte entry leads to degradation of autoreactive CD8 T cells. Proc Natl Acad Sci U S A (2011) 1.89
Toll-like receptor 4 mediates innate immune responses to Haemophilus influenzae infection in mouse lung. J Immunol (2002) 1.88
DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. J Hepatol (2011) 1.85
Interleukin 21 controls tumour growth and tumour immunosurveillance in colitis-associated tumorigenesis in mice. Gut (2011) 1.84
ESAM supports neutrophil extravasation, activation of Rho, and VEGF-induced vascular permeability. J Exp Med (2006) 1.75
Activated Nrf2 impairs liver regeneration in mice by activation of genes involved in cell-cycle control and apoptosis. Hepatology (2014) 1.73
Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. J Hepatol (2010) 1.73
Induction of IL-13 triggers TGF-beta1-dependent tissue fibrosis in chronic 2,4,6-trinitrobenzene sulfonic acid colitis. J Immunol (2007) 1.69
Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation (2004) 1.68
Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology (2010) 1.65
NOD1 contributes to mouse host defense against Helicobacter pylori via induction of type I IFN and activation of the ISGF3 signaling pathway. J Clin Invest (2010) 1.64
Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation (2006) 1.64
Fatal pneumonia caused by Panton-Valentine Leucocidine-positive methicillin-resistant Staphylococcus aureus (PVL-MRSA) transmitted from a healthy donor in living-donor liver transplantation. Transplantation (2006) 1.63
Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci (2009) 1.60
Intestinal ischemia: current treatment concepts. Langenbecks Arch Surg (2010) 1.60
Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J Exp Med (2009) 1.59
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59
Impact of quality as well as quantity of skeletal muscle on outcomes after liver transplantation. Liver Transpl (2014) 1.58
Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest (2002) 1.57
Bile duct damage after cold storage of deceased donor livers predicts biliary complications after liver transplantation. J Hepatol (2013) 1.56
Elevated adiponectin serum levels in patients with chronic alcohol abuse rapidly decline during alcohol withdrawal. J Gastroenterol Hepatol (2008) 1.56
GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. Am J Pathol (2009) 1.54
Quality of life and functional long-term outcome after partial pancreatoduodenectomy: pancreatogastrostomy versus pancreatojejunostomy. Ann Surg Oncol (2005) 1.52
IL-13 signaling via IL-13R alpha2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis. Gastroenterology (2008) 1.51
Donor morbidity in right and left hemiliver living donor liver transplantation: the impact of graft selection and surgical innovation on donor safety. Transpl Int (2014) 1.51
Completion thyroidectomy: effect of timing on clinical complications and oncologic outcome in patients with differentiated thyroid cancer. World J Surg (2012) 1.50
Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology (2009) 1.47
Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. J Clin Invest (2007) 1.47
Pre- and perioperative factors affecting infection after living donor liver transplantation. Nutrition (2012) 1.46
Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer. Clin Cancer Res (2002) 1.44
Cytomegalovirus in transplantation - challenging the status quo. Clin Transplant (2007) 1.43
Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesis. Am J Pathol (2004) 1.42
High volume naked DNA tail-vein injection restores liver function in Fah-knock out mice. J Gastroenterol Hepatol (2010) 1.42
Kidney transplant in children weighing less than 15 kg: donor selection and technical considerations. Transplantation (2002) 1.41
Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res (2003) 1.41
Increased intratumor Valpha24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas. Clin Cancer Res (2005) 1.40
Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation (2004) 1.40
Pumpless extracorporeal interventional lung assist in patients with acute respiratory distress syndrome: a prospective pilot study. Crit Care (2009) 1.40
Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol (2009) 1.34
GLUT1 as a therapeutic target in hepatocellular carcinoma. Expert Opin Ther Targets (2009) 1.34
The liver: a special case in transplantation tolerance. Semin Liver Dis (2007) 1.33
Google goes cancer: improving outcome prediction for cancer patients by network-based ranking of marker genes. PLoS Comput Biol (2012) 1.32
Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population. Am J Hum Genet (2012) 1.32
Absence of smooth muscle actin-positive pericyte coverage of tumor vessels correlates with hematogenous metastasis and prognosis of colorectal cancer patients. Oncology (2005) 1.32
Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer (2007) 1.30
Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut (2010) 1.29
Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol Cancer Ther (2007) 1.29
Surgical strategy in aortoesophageal fistulae: endovascular stentgrafts and in situ repair of the aorta with cryopreserved homografts. Ann Surg (2007) 1.29
The Nrf2 transcription factor protects from toxin-induced liver injury and fibrosis. Lab Invest (2008) 1.27
Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the ONE study. Transplant Res (2013) 1.27
Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. Mol Cancer Ther (2011) 1.26
Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2. Cancer Res (2008) 1.26
Cutting Edge: Immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients. J Immunol (2011) 1.25
Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80+CD11b(high)Gr1(low) macrophages. J Clin Invest (2011) 1.25
Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol (2004) 1.25
A cell-based approach to the minimization of immunosuppression in renal transplantation. Transpl Int (2008) 1.24
mTOR, cancer and transplantation. Am J Transplant (2008) 1.24
Role of TLR9 in hepatic stellate cells and experimental liver fibrosis. Biochem Biophys Res Commun (2008) 1.23